NEW YORK, March 18, 2021 /PRNewswire/ --
The global monoclonal antibodies market is expected to grow by USD 63.41 billion during 2021-2025, as per Technavio. This marks a significant market slow down compared to the 2020 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. However, healthy growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of over 8%.
For the Right Perspective & Competitive Insights. Make confident decisions using our benchmarks and analysis.
Download FREE Sample Report
Read the 120-page report with TOC on "Monoclonal Antibodies Market Analysis Report by Application (Oncology, Autoimmune disorders, Infectious Diseases, and Other applications) and Geography (North America, Europe, Asia, and ROW), and the Segment Forecasts, 2021-2025". Gain competitive intelligence about market leaders. Track key industry opportunities, trends, and threats. Information on marketing, brand, strategy and market development, sales and supply functions.
More Details: https://www.technavio.com/report/report/monoclonal-antibodies-market-industry-analysis
The monoclonal antibodies market is driven by the introduction of low-priced biosimilar monoclonal antibodies. In addition, the targeted therapeutic mechanism of action is anticipated to boost the growth of the monoclonal antibodies market.
The introduction of biosimilars aimed at curbing the increasing year-over-year cost of healthcare and could be instrumental in reducing the cost of medication. The number of clinical trials for a biosimilar is comparatively lesser than that needed for the original biologic drug. The strategies adopted by manufacturers of biosimilars to ensure reduced cost include investing initially in advanced production processes with the help of single-use technology to keep production costs low and acquiring a good understanding of the regulatory process. This helps in developing biosimilars that are compliant with the regulations and also in reducing the cost of regulatory processing. Another major step to control the cost of delayed entry would be to limit patent litigation to avoid delay in market entry and to invest in physician and patient education to increase awareness about biosimilars.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Major Five Monoclonal Antibodies Companies:
AstraZeneca Plc
AstraZeneca Plc operates business through the Unified Business segment. It is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of PD-L 1 with the PD-1 and CD80 molecules.
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co. operates business through the Unified segment. It is nivolumab a PD-1 inhibitor monoclonal antibody approved for the treatment of various head and neck cancers, including oral cancer.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. operates business through Pharmaceuticals and Diagnostics. The company offers TECENTRIQ. It is atezolizumab, a monoclonal antibody, sold under the brand name TECENTRIQ for treating various cancers.
GlaxoSmithKline Plc
GlaxoSmithKline Plc operates business through Pharmaceuticals, Consumer Healthcare, and Vaccines. The company offers NUCALA. It is mepolizumab sold under the brand name NUCALA which is used as maintenance treatment for patients 6 and older with severe eosinophilic asthma.
Johnson & Johnson
Johnson & Johnson operates business through Pharmaceutical and Medical Devices. The company offers REMICADE. It is a chimeric IgG1K monoclonal antibody used for the treatment of multiple autoimmune disorders.
Monoclonal Antibodies Market Application Outlook (Revenue, USD billion, 2020-2025)
- Oncology - size and forecast 2020-2025
- Autoimmune disorders - size and forecast 2020-2025
- Infectious diseases - size and forecast 2020-2025
- Other applications - size and forecast 2020-2025
Monoclonal Antibodies Market Geography Outlook (Revenue, USD billion, 2020-2025)
- North America - size and forecast 2020-2025
- Europe - size and forecast 2020-2025
- Asia - size and forecast 2020-2025
- ROW - size and forecast 2020-2025
Are you a start-up willing to make it big in the business? Download FREE Sample Report
Related Reports on Health Care Include:
Global Alcoholic Hepatitis Treatment Market- The alcoholic hepatitis treatment market is segmented by type (corticosteroids, xanthine derivatives, and others), geography (North America, Europe, Asia, and ROW), and key vendors.
To get extensive research insights: Download FREE Sample Report
Global Mycosis Fungoides Therapeutics Market- The mycosis fungoides therapeutics market is segmented by type (small molecules and biologics), geography (North America, Europe, Asia, and ROW), and key vendors.
To get extensive research insights: Download FREE Sample Report
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
Report Page: https://www.technavio.com/report/monoclonal-antibodies-market-industry-analysis
SOURCE Technavio
Share this article